Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
APHINITY: Adding pertuzumab to trastuzumab plus chemotherapy in patients with op...
Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium
APHINITY: Adding pertuzumab to trastuzumab plus chemotherapy in patients with operable HER2-positive early breast cancer ( Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium )
18 Dec 2019
Breast cancer incidence in post-menopausal women: Long-term influence of oestrog...
Prof Rowan Chlebowski - City of Hope National Medical Center, Duarte, USA
Breast cancer incidence in post-menopausal women: Long-term influence of oestrogen plus progestin versus oestrogen alone ( Prof Rowan Chlebowski - City of Hope National Medical Center, Duarte, USA )
18 Dec 2019
Could trastuzumab deruxtecan become the new standard of care for pretreated HER2...
Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA
Could trastuzumab deruxtecan become the new standard of care for pretreated HER2-positive breast cancer patients? ( Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA )
18 Dec 2019
Addition of S-1 to post-operative endocrine therapy for patients with hormone re...
Prof Masakazu Toi - Kyoto University, Kyoto, Japan
Addition of S-1 to post-operative endocrine therapy for patients with hormone receptor-positive HER2-negative breast cancer ( Prof Masakazu Toi - Kyoto University, Kyoto, Japan )
18 Dec 2019
Pertuzumab plus trastuzumab and chemotherapy continues to show benefit in HER2-p...
Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium
Pertuzumab plus trastuzumab and chemotherapy continues to show benefit in HER2-positive breast cancer ( Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium )
18 Dec 2019
Trastuzumab deruxtecan yields promising results in HER2-positive breast cancer p...
Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA
Trastuzumab deruxtecan yields promising results in HER2-positive breast cancer patients pretreated with TDM-1 ( Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA )
18 Dec 2019
QUANTUM-R: Transfusion independence in patients with FLT3-ITD-mutated R/R AML tr...
Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA
QUANTUM-R: Transfusion independence in patients with FLT3-ITD-mutated R/R AML treated with quizartinib or salvage chemotherapy ( Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA )
18 Dec 2019
Safety and efficacy of the novel BTK inhibitor zanubrutinib in patients with CLL...
Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia
Safety and efficacy of the novel BTK inhibitor zanubrutinib in patients with CLL/SLL ( Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia )
18 Dec 2019
Ibrutinib plus venetoclax for the first-line treatment of CLL/SLL: Results from ...
Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia
Ibrutinib plus venetoclax for the first-line treatment of CLL/SLL: Results from the CAPTIVATE study ( Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia )
18 Dec 2019
KEYNOTE-522 updates: Pembrolizumab plus neoadjuvant chemotherapy in early triple...
Prof Peter Schmid - St Bartholomew's Hospital London, London, UK
KEYNOTE-522 updates: Pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast cancer ( Prof Peter Schmid - St Bartholomew's Hospital London, London, UK )
18 Dec 2019
LYRA: Maintenance therapy with daratumumab improves depth of response and achiev...
Dr Robert Rifkin - Rocky Mountain Cancer Centers, Denver, USA
LYRA: Maintenance therapy with daratumumab improves depth of response and achieves durable remissions in MM patients ( Dr Robert Rifkin - Rocky Mountain Cancer Centers, Denver, USA )
17 Dec 2019
KRd consolidation in MM patients with a positive PET-CT after standard first-lin...
Dr Fredrik Schjesvold - Oslo University Hospital, Oslo, Norway
KRd consolidation in MM patients with a positive PET-CT after standard first-line therapy: Results from the phase II CONPET trial ( Dr Fredrik Schjesvold - Oslo University Hospital, Oslo, Norway )
17 Dec 2019